Understanding COVID-19 pathophysiology in rheumatoid arthritis is crucial for a better understanding of the disease and the development of more effective treatments. TLR7 recognises pathogenic singlestranded RNAs (ssRNAs) and plays a crucial role in the innate immune response to viral infections and autoimmune disorders. Recent evidence has suggested that selective, specific antagonists for TLR7 might be more beneficial in certain diseases, such as rheumatoid arthritis (RA). Thus, the use of novel small molecule TLR7 inhibitors with a larger safety window and differentiated selectivity may potentially have significant clinical utility in COVID infection with RA condition. Herein, we review efforts to develop novel TLR7 antagonists. According to current findings, repurposing existing available compounds will result in more effective functioning than using newly designed medications. Based on this fact, we used natural compounds, and a computational study has been conducted. This comprises the screening of these drugs' binding affinity with TLR7, which is upregulated in COVID infection as well as the RA condition. The results show that the top six scores achieved by toll-like receptors (PDB ID: 6LW1) are, viz., -13.8036, -13.4501, -13.3095, -12.5435, -11.4339, and -10.5996, for ZINC08635349, ZINC12602116, ZINC08635473, ZINC08635326, ZINC08635431, and ZINC20112269, Thus, the compounds discovered through the use of various softwares can possibly be used for the management of rheumatoid arthritis during and after COVID infection. Hence, we can conclude that these molecules show good activity in reducing the activity of TLR7.